CND Life Sciences Celebrates Opening of New Innovation Laboratory with Ribbon-Cutting Ceremony

Laboratory expands product development and research capabilities to advance neurodiagnostics

SCOTTSDALE, Ariz., Sept. 17, 2026 /PRNewswire/ -- CND Life Sciences, Inc. (CND), a medical technology company that advances neurodiagnostic tests and associated biomarker solutions, today announced the opening of its new Innovation Laboratory in Scottsdale. The opening was commemorated with a ribbon-cutting ceremony.

The laboratory complements CND's existing infrastructure and supports the Company's long-term growth by advancing priority research, innovation, and product-development programs. Separate from CND's CLIA-certified, CAP-accredited, and CLEP-permitted clinical laboratory operations, the Innovation Laboratory provides dedicated space for assay development, biomarker research, technology evaluation, and translational research programs.

"The opening of our Innovation Laboratory marks an important milestone for CND," said Todd Levine, MD, CND's Chief Medical Officer and Co-Founder. "This facility reflects our commitment to investing in our people, scientific capabilities, and long-term vision, helping us better serve clinicians, patients, researchers, and partners."

Located near CND's headquarters and central laboratory operations in Scottsdale, the Innovation Laboratory enables close collaboration among the Company's scientific, product development, operational, and leadership teams. It provides access to the talent and infrastructure needed to support CND's next phase of growth. The facility also reflects CND's continued investment in Arizona's growing biotechnology and medical technology community.

"The Innovation Laboratory strengthens our ability to explore new scientific opportunities, advance the future of precision neurodiagnostic, medicine and support development of novel therapeutic treatments for degenerative diseases" said Christopher Gibbons, MD, Chief Scientific Officer and Co-Founder of CND Life Sciences. "By creating a focused environment for scientific expansion, the facility will help us move promising ideas forward and continue building on the work that drives our mission."

CND celebrated the opening with a ribbon-cutting ceremony attended by employees, community members, and key stakeholders. The laboratory will begin operations next week.

About CND Life Sciences
CND Life Sciences supports the care of patients facing the potential diagnosis of a neurodegenerative disease. Operating a CLIA-certified, CAP-accredited, and CLEP-permitted laboratory in Scottsdale, Arizona, CND offers the Syn-One Test^® as a laboratory developed test (LDT) to aid clinicians in the diagnostic evaluation of patients with suspected synucleinopathies that include Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and other related disorders. Syn-One uses proprietary techniques to detect phosphorylated alpha-synuclein in cutaneous nerves while also measuring other signs of peripheral nerve degeneration. In a prospective, multicenter NIH-sponsored study published in the Journal of the American Medical Association (JAMA) in 2024, phosphorylated alpha-synuclein was demonstrated in 95.5% of participants clinically diagnosed with a synucleinopathy.¹ 

More than 3,500 clinicians have used the Syn-One Test in the diagnostic evaluation of more than 70,000 patients. The company also collaborates with biopharmaceutical companies on clinical trials for investigational therapies and is conducting studies on early disease detection and synuclein quantification. For more information, visit cndlifesciences.com or connect with us on LinkedIn.

CND Media Contact:
[email protected] 

CND Company Contact:
Jennifer Whitney
Director, Brand Marketing
[email protected]

¹Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792.

SOURCE CND Life Sciences